CareDx Q2 revenue $92.3M (+31% YoY); raises FY2024 revenue guidance to $320-$328M

CareDx, Inc.

2024-Q2 EPS reported -$0.35 revenue$164,323,000

Total revenue $92.3M (+31% YoY); Testing Services revenue $70.9M (+33%); volume 43,700 tests (+17%).
GAAP net loss narrowed to $1.4M from $25M; non-GAAP net income $13.6M (vs loss of $9.9M).
Adjusted EBITDA positive $12.9M vs loss of $10.4M; cash $228.9M, no debt.
Raised FY2024 revenue guidance to $320-$328M (from $274-$282M); adjusted EBITDA guidance to $9-$15M gain.
Expanded coverage by 27M lives in H1 2024; published SHORE study and Nature Medicine data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.